Jaime P Almandoz MD MBA FTOS (He/Him)
Obesity
Medical Director, Weight Wellness Program Associate Professor, Division of Endocrinology
Join to view full profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-2800
Fax+1 214-645-8697
Dr. Almandoz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UT Dallas Naveen Jindal School of Management and UT SouthwesternMBA, Healthcare Management Executive MBA, 2016 - 2019
University of Texas Southwestern Medical CenterFellowship, Nutrition & Metabolic Diseases, 2012 - 2013
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 2009 - 2012- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2007 - 2009
Royal College of Surgeons IrelandClass of 2004
Certifications & Licensure
TX State Medical License 2012 - 2027
MN State Medical License 2009 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- Member (MRCPI) Royal College of Physicians of Ireland, 2006
Publications & Presentations
PubMed
- Discordance between adiposity and FIB-4 risk classification in US adults.Luyu Xie, Diego Anazco, Azucena Herrera Chancay, Sarah E Messiah, Jaime P Almandoz
Journal of Diabetes and Metabolic Disorders. 2026-12-01 - Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/mand adiposity-related complications: A post hoc analysis of the ATTAIN-1 t...Jaime P Almandoz, Alexander Dimitri Miras, Matthias Blüher, Pedro Orozco Del Pino, Donna Mojdami
Obesity Pillars. 2026-12-01 - Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Jaime P Almandoz, Beverly G Tchang, Kelley Myers, Andrea Traina, Jigish Bhavsar
Diabetes, Obesity & Metabolism. 2026-12-01
Press Mentions
Cost and Access Are Barriers to Broader GLP-1 Use, but Experts Say There Are SolutionsOctober 15th, 2025- Eli Lilly’s Weight Loss Pill Orforglipron Clears Its Latest Trial, Paving Way for ApprovalAugust 26th, 2025
- New Type 2 Diabetes Guidance Ties Treatment Choice to Cardio-Renal RiskAugust 22nd, 2025
Professional Memberships
- Member
- Member
- Member
- Member
External Links
- UT Southwestern Medical Centerhttp://profiles.utsouthwestern.edu/profile/140270/jaime-almandoz.html
- Weight Wellness Programhttp://www.utswmedicine.org/hospitals-clinics/aston/internal-medicine/weight-wellness.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: